Gilead Sciences

Open: 83.74 Close: 83.55 Change: -0.19

Our AI found unexpected things about Gilead Sciences Company Inc Stock.

This document will help you to evaluate Gilead Sciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, Inc, stock, GILD, compare, competitor, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences Inc. stock underperforms t Tuesday when compared to competitors - marketwatch.inc. The company has 1,247,105,100 shares outstanding. Dodge & Cox is among the largest hedge funds holding Gileads.

Today's News

Gilead Sciences Inc. stock underperforms t Tuesday when compared to competitors - marketwatch.com. Gileads Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes therapies. Gilead Sciences Inc. stock underperforms wed Wednesday when compared to competitors - marketwatch.inc. gilead sciences inc. stock outperforms wednesday when compared with competitors. Gilead Sciences, Inc. announces its Q123 earnings on Thursday, 27th April 27th. Q1 and Q2 are weaker quarters for Gileade Sciences, owing to its HIV division. Gilead Sciences is scheduled to report 1st quarter earnings on 04/27/2023, after the market closes. Dodge & Cox is among the largest hedge funds holding Gileads share valued at 3B. The company has 1,247,105,100 shares outstanding. On April 27, 2023, Gilead Sciences Inc. (GILD) stock closed at $83.51, according to data from CNN Money. The current consensus among 29 polled investment analysts is to hold stock. Baird Reaffirms Their Hold Rating on Gilead Sciences (GILD) Baird maintained a Hold rating on Giledad Sciences with a price target of $80.00. Currently, the analyst consensus on Gilesad Sciences is a Moderate Buy with an average price target. Gilead Sciences reported mixed first-quarter financial results on Thursday afternoon. Sales of cancer and HIV drugs rose, while sales of Covidiral antiviral drugs fell. Gilead Sciences Inc. (GILD) stock price, quote & news - stock analysis. Robinhood gives you the tools you need to put your money in motion. GILD has outperformed the market over the past 20 years. Gilead Sciences, Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gileade Sciences Inc. announced its first quarter 2023 financial results.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, Inc, stock, GILD, compare, competitor, and the most common words in the summary are: gilead, science, stock, inc, market, report, gild, . One of the sentences in the summary was: Gilead Sciences Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #stock #inc #market #report #gild.